OrbiMed Capital GP VII LLC
CIK 1760648 · last filed 2025-12-18
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$232.38M
Companies
11
Total Filings
31
Lifetime Open-Market Net
$225.95M
Filer Profile
Reported Address
601 LEXINGTON AVENUE, 54TH FLOORNEW YORK, NY 10022
Phone
(212) 739-6491
State of Incorporation
DE
Related Filers
ORBIMED ADVISORS LLC — 91 joint filings, latest 2026-06-24
OrbiMed Genesis GP LLC — 43 joint filings, latest 2026-06-24
ORBIMED CAPITAL LLC — 24 joint filings, latest 2024-04-05
OrbiMed Advisors Israel II Ltd — 9 joint filings, latest 2023-08-17
OrbiMed Israel GP II, L.P. — 9 joint filings, latest 2023-08-17
OrbiMed Capital GP VIII LLC — 6 joint filings, latest 2024-11-05
OrbiMed Advisors III Ltd — 5 joint filings, latest 2024-07-17
OrbiMed Asia GP III, L.P. — 5 joint filings, latest 2024-07-17
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses.
View filings on SEC EDGAR.
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| KROS | Director | 45,057 | $11.08 | $499.2K | $18.01M | 2 | 2025-12-18 |
| PASG | 10%+ Owner | 313,980 | $5.00 | $1.57M | $17.76M | 13 | 2025-06-26 |
| MBX | Director | 3,205,930 | $59.02 | $189.21M | $6.06M | 1 | 2025-02-19 |
| Theseus Pharmaceuticals, Inc. (THRX) Delisted | Director | 0 | $4.06 | $0 | $7.74M | 3 | 2024-02-14 |
| Damora Therapeutics, Inc. (GLTO) Delisted | Director | 36,571 | $28.69 | $1.05M | $52.66M | 2 | 2023-07-17 |
| Kinnate Biopharma Inc. (KNTE) Delisted | Director | 794,368 | $2.65 | $2.11M | $70.72M | 2 | 2023-05-02 |
| Terns Pharmaceuticals, Inc. (TERN) Delisted | Director | 762,400 | $52.95 | $40.37M | $5.00M | 1 | 2022-12-28 |
| Sierra Oncology, Inc. (SRRA) Delisted | Director | 226,704 | $54.99 | $12.47M | $0 | 1 | 2022-01-28 |
| JANX | Director | 2,403,566 | $17.10 | $41.10M | -$22.50M | 1 | 2021-12-17 |
| Repare Therapeutics Inc. (RPTX) Delisted | Director | 97,293 | $2.65 | $257.8K | $40.50M | 3 | 2021-09-02 |
| Enliven Therapeutics, Inc. (IMRA) Delisted | Director | 633,100 | $14.59 | $9.24M | $30.00M | 1 | 2021-07-16 |
Recent Filings · Page 3 of 4
31 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-01-21 | Theseus Pharmaceuticals, Inc. (THRX) Delisted | Buy (P) | +475,251 | $4.74M | EDGAR |
| 2022-01-13 | PASG | Buy (P) | +300,000 | $1.68M | EDGAR |
| 2021-12-17 | JANX | Sell (S) | −1,179,900 | -$22.50M | EDGAR |
| 2021-09-02 | Repare Therapeutics Inc. (RPTX) Delisted | Sell (S) | −113,592 | -$3.87M | EDGAR |
| 2021-08-19 | Repare Therapeutics Inc. (RPTX) Delisted | Sell (S) | −60,984 | -$2.08M | EDGAR |
| 2021-07-16 | Enliven Therapeutics, Inc. (IMRA) Delisted | Buy (P) | +4,999,998 | $30.00M | EDGAR |
| 2020-12-04 | Kinnate Biopharma Inc. (KNTE) Delisted | Buy (P) | +2,250,000 | $45.00M | EDGAR |
| 2020-11-04 | Damora Therapeutics, Inc. (GLTO) Delisted | Mixed | +19,016,275 | $55.00M | EDGAR |
| 2020-06-25 | Repare Therapeutics Inc. (RPTX) Delisted | Mixed | +10,126,575 | $46.45M | EDGAR |
| 2020-04-13 | KROS | Mixed | +3,806,202 | $18.01M | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.